

Bioheart to Present at BioFlorida's Saturday Exchange

SUNRISE, Fla. – February 15, 2012 – [Bioheart](#) (BHRT.OB), a leader in developing stem cell therapies to treat cardiovascular diseases, today announced that they have been chosen as a presenter in the BioFlorida Saturday Exchange conference later this month.

"The Saturday Exchange brings together many professionals to discuss the field of biotechnology," said Mike Tomas, Bioheart's president and CEO. "Bioheart is excited about the opportunity to represent the South Florida community and share our experiences in the field of regenerative medicine."

BioFlorida is the voice of Florida's bioscience industry representing more than 3,000 companies and research organizations in the biotechnology, pharmaceutical and medical device fields employing 61,000 Floridians. BioFlorida's member-driven initiatives provide a strong business climate for production of quality, life-improving technologies and promote economic benefits to the state.

The Saturday Exchange is a reprise of the successful Biomed Exchange meeting, held for many years during the 1980-90s. More than 100 life science professionals gathered in Miami on a Saturday morning each month to learn about various aspects of the community's growing life sciences cluster. The 2012 Exchange will take place at University of Miami's Life Science & Technology Park.

The Keynote Speaker is Bioheart's Chairman William P. Murphy Jr., MD who will share his career experiences and insights as a leading entrepreneur in the medical device industry, spanning the founding of Cordis Corporation to more recent ventures. In addition, Mike Tomas, Bioheart's president and CEO and Kristin Comella, Bioheart's CSO will present the use of stem cells in degenerative diseases.

About Bioheart

[Bioheart](#) (BHRT.OB) is committed to developing stem cell therapies to treat congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other medical problems. The company focuses on the discovery and development of therapies that will improve patients' quality of life and reduce health care costs and hospitalizations. Bioheart's leading product, MyoCell, is a muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart to improve cardiac function. For more information, visit www.bioheartinc.com.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.

###